WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , Scientific Journal Impact Factor (SJIF) , IFSIJ Measure of Journal Quality , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , Research Publication Rating and Indexing , Doi-Digital Online Identifier , ISSN National Centre , Zenodo Indexing , International CODEN Service, USA , 

ISSN 2457-0400

Impact Factor  :  7.675

WJAHR Citation

  All Since 2020
 Citation  105  60
 h-index  4  4
 i10-index  3  2

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased from  5.464 to 7.675 for Year 2026.

  • WJAHR: APRIL ISSUE PUBLISHED

    APRIL 2026 Issue has been successfully launched on 1 APRIL 2026.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR April 2026 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

Best Article Awards

World Journal of Advance Healthcare Research (WJAHR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.

Best Article of current issue

Download Article : Click here

Indexing

  Indexing

  • Google Scholar
  • Index Copernicus
  • SOCOLAR, China
  • Research Bible, Fuchu, Tokyo. JAPAN
  • Cosmos Impact Factor
  • Scientific Indexing Services (SIS)
  • UDLedge Science Citation Index
  • International Impact Factor Services
  • International Society for Research Activity (ISRA) Journal Impact Factor (JIF)
  • Scientific Journal Impact Factor (SJIF)
  • IFSIJ Measure of Journal Quality
  • International Scientific Indexing, UAE (ISI) (Under Process)
  • International Impact Factor Services (IIFS)
  • Web of Science Group (Under Process)
  • Directory of Research Journals Indexing
  • Scholar Article Journal Index (SAJI)
  • International Scientific Indexing ( ISI )
  • Academia
  • Scope Database
  • Research Publication Rating and Indexing
  • Doi-Digital Online Identifier
  • ISSN National Centre
  • Zenodo Indexing
  • International CODEN Service, USA

Abstract

COMPARATIVE STUDY BETWEEN CYTOREDUCTIVE SURGERY ALONE VERSUS CYTOREDUCTIVE SURGERY AND HYPERTHERMIC INTRA-PERITONEAL CHEMOTHERAPY IN IRAQI PATIENT WITH DIFFUSE INTRAPERITONEAL CARCINOMATOSIS

*Mohammed Saad Yas, Aqeel Shakir Mahmood, Abbas Ali Hasan

ABSTRACT

Background: Peritoneal Carcinomatosis (PC) remains a major therapeutic challenge. Cytoreductive surgery (CRS) combined with Hyperthermic Intraperitoneal chemotherapy (HIPEC) is increasingly adopted, but local evidence from low- and middle-income settings is limited. We evaluated outcomes of CRS alone versus CRS+HIPEC in an Iraqi cohort. Methods: We performed a prospective cohort study of 100 consecutive PC patients(2021–2025) treated with CRS alone (n=50) from total (217 cases) or CRS+HIPEC (n=50)from total (71 cases). Baseline variables included age, sex, primary tumor type, Peritoneal Cancer Index (PCI), and neoadjuvant therapy. Primary endpoints were overall survival (OS) and peritoneal relapse-free survival (PRFS). Secondary endpoint was postoperative performance status. Group comparisons used Welch’s t-test when variances were unequal and Student’s t-test otherwise; categorical variables were compared with chi-square tests. Results: Groups were balanced at baseline: mean age 58.86±7.48 (CRS) vs. 58.46±8.13 years (CRS+HIPEC); PCI 11.00±3.12 vs 10.88±3.44 (both p>0.05). Females comprised 86% in each arm; primaries were ovarian (68%), colonic (12%), gastric (12%), and appendiceal (8%); neoadjuvant therapy was used in 74% per group. CRS+HIPEC achieved longer OS (37.90±16.03 vs 19.42±8.45 months; mean difference 18.48 months; 95% CI 3.38–13.58; p=0.001, Welch’s) and longer PRFS (28.34±13.32 vs 15.36±5.58 months; mean difference 12.98 months; 95% CI 8.90–17.06; p<0.001, Welch’s). Performance status was better (lower score) after CRS+HIPEC (8.58±2.60 vs 11.06±2.94; mean difference 2.48; 95% CI 1.38–3.58; p<0.001). Conclusion: In this single-center Iraqi cohort, adding HIPEC to complete Cytoreductive surgery was associated with clinically meaningful improvements in survival and postoperative function compared with CRS alone, with balanced baseline characteristics. These findings support adopting CRS+HIPEC for carefully selected patients within standardized pathways; prospective multicenter evaluation with time-to-event methods and comprehensive toxicity reporting is warranted.

[Full Text Article] [Download Certificate]